Phase 3 N=114 Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Bleeding
Primary: Chest Tube Drainage — 200; 225; 375; 400 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=177 Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
Scoliosis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 1775; 2116; 1531 ml
N/A N=100 Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
Cardiopulmonary Bypass
Primary: Total Transfusion Amounts — 161; 116 mililiters — p=0.35
Early Phase 1 N=15 Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation
Rosacea
Primary: Kallikrein 5 (KLK5) Protease Activity — 581.1; 816.5 RFU/uL
Phase 4 N=28 The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO
E-Aminocaproic Acid · Bilateral Varus Rotational Osteotomy
Primary: Intraoperative Calculated Total Blood Loss — 535.7; 628.0 mL
Phase 4 N=21 A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery
Pediatric Cardiac Surgery · Complication of Extracorporeal Circulation
Primary: Inflammatory Markers/Cytokines — 1.5; 2.1; 1.6; 2.2 pg/dl
Phase 4 N=246 TXA vs. Amicar in Total Knee and Hip Arthroplasty
Blood Loss · Hip Arthritis · Knee Arthritis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 934.1; 948.7; 660.6; 891.2 milliliters — p=<0.05
Phase 4 N=955 Prospective Trial of Tranexamic Acid in Cardiac Surgery
C.Surgical Procedure; Cardiac
Primary: Postoperative Blood Loss — 520; 490; 450 ml
Phase 3 N=11,000 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Obstetrical Complications · Hemorrhage · Labor and Delivery
Primary: Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells — 201; 233 Participants — p=0.19
Phase 2 N=150 Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury
Hemorrhage · Shock · Wounds and Injuries
Primary: Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA)." — 0.503; 0.509; 0.532 fold…
Phase 4 N=36 Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty
Femoral Neck Fractures
Primary: Number of Participants Who Needed Transfusions — 0; 5 Participants
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
N/A N=260 Tranexamic Acid in Off-pump Coronary Surgery
Off Pump Coronary Artery Bypass Surgery
Primary: Number of Patients Required Allogenic Red Blood Cells Transfusion — 37; 54 participants — p=<0.05
Phase 3 N=903 Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
Traumatic Hemorrhage
Primary: 30 Day Mortality — 36; 45 Participants
Phase 3 N=110 Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Post Partum Hemorrhage · Fibrinolysis; Hemorrhage · Blood Loss
Primary: Blood Volume Loss — 2274; 2407 milliliters
Phase 4 N=14 Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
Placenta Accreta · Postpartum Hemorrhage · Cesarean Section
Primary: Estimated Blood Loss (EBL) — 3116; 9420 cc
Phase 3 N=34 Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
Hemophilia A With Inhibitors
Primary: Number of Bleeds During 6 Month Treatment Period — 13.1; 5.0 bleeds — p=<0.001
Phase 4 N=150 Tranexamic Acid in Knee Joint Surgery
Osteoarthritis
Primary: Blood Loss — 1090; 716; 746 mls — p=<0.05
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
N/A N=89 Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy
Dysplasia, Congenital Hip
Primary: Calculated Total Blood Loss — 1264.6; 1515.4 mL
Phase 4 N=84 Tranexamic Acid Dosing for Total Joint Arthroplasty
Arthropathy of Hip · Arthropathy of Knee
Primary: Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1) — 2.15; 2.06; 2.11 g/dl
Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery
Coronary Artery Disease
Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493
Phase 3 N=616 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
Hematologic Neoplasms · Hemorrhage · Hematopoietic Stem Cell Transplantation
Primary: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned…
N/A N=17 Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study
Menorrhagia
Primary: To Assess the Efficacy of Oral TA and COCP in Adolescents With Menorrhagia. — 536.4; 430.6; 15.6; 16.75 Scores on a scale — p=0.01
Phase 4 N=100 Tranexamic Acid in Surgery of Advanced Ovarian Cancer
Ovarian Cancer
Primary: Perioperative Bleeding Volume — 520; 730 milliliter — p=0.03
Phase 3 N=288 A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
Menorrhagia
Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants
Phase 3 N=87 The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
Acetabular Fractures
Primary: Allogenic Blood Transfusion Rates — 21; 13 Participants
N/A N=25 Tranexamic Acid and Blood Clots in Knee Surgery
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
N/A N=88 Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid
Acetabulum Fractures
Primary: Intra-operative Blood Loss — 727.6; 560.1 Milliliters
Phase 2 N=43 Prevention of Postpartum Hemorrhage With Tranexamic Acid
Postpartum Hemorrhage
Primary: PK Model Parameter Estimates — 8.85; 10.39; 9.45 L/hr